About 2% (6/309) of all patients and as many as 25% (4/16) of patients with high-grade astrocytomas carried germline mutations in MMR genes, which for some patients meant that immunotherapy could be initiated. Here, MRC1 is linked to astrocytoma (excluding glioblastoma).